# GM-CSF for Reversal of Immunoparalysis in Pediatric Sepsis-induced MODS

> **NCT05266001** · PHASE3 · COMPLETED · sponsor: **Nationwide Children's Hospital** · enrollment: 141 (actual)

## Conditions studied

- Pediatric Sepsis-induced Multiple Organ Dysfunction Syndrome

## Interventions

- **DRUG:** GM-CSF
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05266001
- **Lead sponsor:** Nationwide Children's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-14
- **Primary completion:** 2025-09-10
- **Final completion:** 2025-09-10
- **Target enrollment:** 141 (ACTUAL)
- **Last updated:** 2026-04-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05266001

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05266001, "GM-CSF for Reversal of Immunoparalysis in Pediatric Sepsis-induced MODS". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT05266001. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*